Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition

The Quick Take
Oral presentation to feature updated data from the dose escalation and dose expansion phases of the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients with relapsed or refractory lower-risk MDS Three poster presentations will highlight data for TAVALISSE®...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
Fleet Management Software Market worth $6.41 billion by 2033 - Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., Nov. 4, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the global fleet management software market is projected to grow from USD…
Business
Levi & Korsinsky Reminds Ryde Group Ltd Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 9, 2026 - RYDE
Forensic research publicly warned on September 9, 2024 that Ryde Group Ltd carried "all the hallmarks" of a pump-and-dump; two days later a securities class…
Business
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 28, 2026 in Tenax Therapeutics, Inc. Lawsuit - TENX
Key Dates and Disclosure Events: a 33-month Tenax timeline traces how the Company allegedly built confidence in TNX-103 across three financings before its…
Business
Levi & Korsinsky Reminds Millrose Properties Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of December 8, 2026 - MRP
Important Information Regarding Section 20(a) Individual Liability Claims: The lawsuit names Millrose's CEO and CFO, who allegedly signed SEC filings pledging…
